XML 31 R104.htm IDEA: XBRL DOCUMENT v2.4.1.9
EARNINGS (LOSS) PER SHARE (Details) (USD $)
In Millions, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Earnings Per Share [Abstract]      
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $ 913.5us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (866.1)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (116.0)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Basic weighted-average number of common shares outstanding 335.4us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 321.0us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 305.4us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Dilutive effect of stock options and RSUs 6.1us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements 0us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements 0us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
Diluted weighted-average number of common shares outstanding 341.5us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 321.0us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 305.4us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:      
Basic (in dollars per share) $ 2.72us-gaap_EarningsPerShareBasic $ (2.70)us-gaap_EarningsPerShareBasic $ (0.38)us-gaap_EarningsPerShareBasic
Diluted (in dollars per share) $ 2.67us-gaap_EarningsPerShareDiluted $ (2.70)us-gaap_EarningsPerShareDiluted $ (0.38)us-gaap_EarningsPerShareDiluted